O aciclovir é um anti-viral usado mundialmente para o tratamento de herpes (do tipo HSV-1 e HSV-2). Acredita-se que o vírus da herpes está presente em cerca de 90% das pessoas em estado de latência. O tratamento principal em casos onde a doença se manifesta, lesões nos lábios e mucosas, é o aciclovir. No Brasil, para renovar ou fazer um novo registro de medicamento, a Agência Nacional de Vigilância Sanitária (ANVISA) exige testes que expõem o fármaco a ambientes extremos (ácido, base, luz, calor, umidade, oxidação) para gerar produtos de degradação que dependendo da concentração no produto acabado, devem ser submetidos a ensaios toxicológicos. O estudo de degradação forçada também permite elucidar a estabilidade intrínseca do fármaco, contribuindo para o entendimento do mecanismo de degradação da substância, o que, posteriormente, ajuda a compreender quais fatores físicos e químicos devem ser controlados para manutenção da estabilidade. Este trabalho tem objetivo de validar um método de análise para quantificação do aciclovir e seus produtos de degradação por cromatografia líquida de interação hidrofílica (Hydrophilic interaction chromatography - HILIC) com detecção por arranjo de diodos (DAD) como também degradar a amostra em diferentes ambientes. / Acyclovir is an anti-viral used worlwide for herpes treatment (HSV-1 and HSV-2 types). It is estimated that herpes virus is present in almost 90% of people in his latent state. Acylcovir is the main treatment in cases where virus expresses itself. In Brazil, to renew or to make a new registration of medicines, National Agency of Sanitary Surveillance (ANVISA) demands tests to expose the medicine to extreme conditions (acid, basic, light, heat, humidity, oxidation) in order to generate degradation products that, depending on the concentration of the row product, will undergoes toxicological assays. The forced degradation study also allow to elucidate the intrinsic stability of medicine, contributing to understand the degradation mechanism of the substance leading to help the understanding of which physical and chemical factors must be controlled to keep stability. The main objective of this work is to validate a method of analysis to quantify acyclovir and his degradation products using Hydrophilic Interaction Liquid Chromatography (HILIC) based on Diode Array detection as well as to degraded the sample in different conditions.

Graduation date: 1992

The skin, by weight, is the largest organ of the body. Human skin serves to provide several important functions that may be classified. in a general context, as protective, maintaining homeostasis and sensing. The outermost layer of the skin, the stratum corneum, has an essential role as a barrier against the transport of water and of chemical and biological agents. In this study acyclovir (ACV), an antiviral used for treating the varicella zoster virus, was used. It is sensible to say that a hydrophilic drug like acyclovir needs a delivery vehicle or penetration enhancer to permeate the skin with more ease. In an attempt to enhance the permeation of acyclovir, it was formulated in a delivery vehicle with the same formulation as for a micro-emulsion. Increasing percentages of the surfactant, Brij 97, were incorporated in the formulation to determine which of the four formulations is indeed a micro-emulsion. A gelating agent. carrageenan, was used to make the emulsion transdermally more applicable; the influence of this component on the transdermal delivery of acyclovir was also determined. Therefore the aim of this study was to determine: -The effect of a drug delivery vehicle on the transdermal delivery of acyclovir; -The specific formulation of a micro-emulsion and -The influence of a gelating agent on the transdermal delivery of acyclovir. Diffusion studies were performed in vertically mounted glass Franz diffusion cells. The epidermis of female abdominal skin, obtained after abdomeoplasty, was heat separated from the dermis. One millilitre of emulsion (0.1%: 1mg/ml ACV) was added to the skin sample in the donor side of the diffusion cell. The control solution had an equivalent amount of active in water and was added to the donor compartment in a separate experiment. The receptor phase was PBS (phosphate buffered solution). The entire receptor phase of the cells was removed every second hour and was replaced with fresh receptor phase at 37°C. The amount of acyclovir in the receptor phase was determined by HPLC analysis. The cumulative amounts of the active that permeated the skin over the 24 hour period were plotted with the slope of the graphs representing the flux in ng/cm²/h. The average flux values of the experimental cells and control cells were compared. Results of the diffusion studies without carrageenan showed that increasing the concentration of the surfactant increased the diffusion of acyclovir. Permeation studies with carrageenan had a totally different outcome. The enhancement ratio of the experimental cells was much lower than that of the control cells. However the experimental cells showed a small increase as the concentration of the surfactant increased. From VanKel dissolution studies it could be seen that release of acyclovir from the emulsion was not a problem and that the active was available for absorption. Confocal studies were done to determine whether there were any vesicles in the emulsions. Vesicles were expected in the 25% Brij 97 emulsion because it was the same formulation as a micro-emulsion, but vesicles could only be found in the 4% and 8% Brij 97 emulsion. A previous study with acyclovir and three different delivery vehicles gave enhancement ratios between 0.32 to 2.92. Values obtained in this study of the 4% and 8% Brij 97 emulsion without carrageenan were more or less the same but the 15% and 25% Brij 97 emulsion had a much higher enhancement ratio. For the emulsions with carrageenan not one exceeded an enhancement ratio of 0.57. More studies still have to be done on micro-emulsions to determine which specific concentration of surfactant forms a micro-emulsion. The active itself and its physicochemical properties also play an important role in the diffusion studies with the specific delivery vehicle and further research has to be done with different model drugs. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2006.

The skin, by weight, is the largest organ of the body. Human skin serves to provide several important functions that may be classified. in a general context, as protective, maintaining homeostasis and sensing. The outermost layer of the skin, the stratum corneum, has an essential role as a barrier against the transport of water and of chemical and biological agents. In this study acyclovir (ACV), an antiviral used for treating the varicella zoster virus, was used. It is sensible to say that a hydrophilic drug like acyclovir needs a delivery vehicle or penetration enhancer to permeate the skin with more ease. In an attempt to enhance the permeation of acyclovir, it was formulated in a delivery vehicle with the same formulation as for a micro-emulsion. Increasing percentages of the surfactant, Brij 97, were incorporated in the formulation to determine which of the four formulations is indeed a micro-emulsion. A gelating agent. carrageenan, was used to make the emulsion transdermally more applicable; the influence of this component on the transdermal delivery of acyclovir was also determined. Therefore the aim of this study was to determine: -The effect of a drug delivery vehicle on the transdermal delivery of acyclovir; -The specific formulation of a micro-emulsion and -The influence of a gelating agent on the transdermal delivery of acyclovir. Diffusion studies were performed in vertically mounted glass Franz diffusion cells. The epidermis of female abdominal skin, obtained after abdomeoplasty, was heat separated from the dermis. One millilitre of emulsion (0.1%: 1mg/ml ACV) was added to the skin sample in the donor side of the diffusion cell. The control solution had an equivalent amount of active in water and was added to the donor compartment in a separate experiment. The receptor phase was PBS (phosphate buffered solution). The entire receptor phase of the cells was removed every second hour and was replaced with fresh receptor phase at 37°C. The amount of acyclovir in the receptor phase was determined by HPLC analysis. The cumulative amounts of the active that permeated the skin over the 24 hour period were plotted with the slope of the graphs representing the flux in ng/cm²/h. The average flux values of the experimental cells and control cells were compared. Results of the diffusion studies without carrageenan showed that increasing the concentration of the surfactant increased the diffusion of acyclovir. Permeation studies with carrageenan had a totally different outcome. The enhancement ratio of the experimental cells was much lower than that of the control cells. However the experimental cells showed a small increase as the concentration of the surfactant increased. From VanKel dissolution studies it could be seen that release of acyclovir from the emulsion was not a problem and that the active was available for absorption. Confocal studies were done to determine whether there were any vesicles in the emulsions. Vesicles were expected in the 25% Brij 97 emulsion because it was the same formulation as a micro-emulsion, but vesicles could only be found in the 4% and 8% Brij 97 emulsion. A previous study with acyclovir and three different delivery vehicles gave enhancement ratios between 0.32 to 2.92. Values obtained in this study of the 4% and 8% Brij 97 emulsion without carrageenan were more or less the same but the 15% and 25% Brij 97 emulsion had a much higher enhancement ratio. For the emulsions with carrageenan not one exceeded an enhancement ratio of 0.57. More studies still have to be done on micro-emulsions to determine which specific concentration of surfactant forms a micro-emulsion. The active itself and its physicochemical properties also play an important role in the diffusion studies with the specific delivery vehicle and further research has to be done with different model drugs. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2006.

Extravasation is a condition that can occur during an intravenous administration. This means that the solution administered intravenously goes extravascular. Depending on physiochemical properties of the substance and solution, this can cause different severity of the damage. Extravasation of acyclovir, potassium phosphate and potassium chloride causes severe tissue damage that can, in worst case, lead to tissue necrosis. The purpose was therefore to investigate how acyclovir, potassium phosphate and potassium chloride causes tissue damage due to pH and osmolality and how the tissue damage can be avoided. To answer the purpose, a comprehensive literature search was conducted on three different databases; Pubmed, CINAHL and Cochrane. The literature search was in progress from February 4 to May 14 2020. The literature search generated a total of 42 articles and case reports, of which 13 of these were relevant for the purpose. These 13 articles consisted of two animal studies, three experimental observational studies, two guidelines from Västra Götalands Region, three case reports about acyclovir and three case reports of potassium phosphate and potassium chloride.   Two of the experimental observational studies showed that potassium chloride could be diluted with 100 mL of 0,9% sodium chloride or 5% dextrose in water to possibly avoid tissue damage due to extravasation. Such results were not found for either acyclovir or potassium phosphate. The conclusion that could be drawn was that acyclovir caused tissue damage because of its alkaline pH, potassium phosphate because of its hyperosmolality and potassium chloride because of its acidic pH and its hyperosmolality. One way to possibly avoid tissue damage caused by extravasation is to dilute the substances with higher dilution volumes. However, due to the lack of reliability of the included studies, it cannot be safely concluded that tissue damage can be avoided.

INTRODUÇÃO: A administração de aciclovir por via sistêmica é o tratamento de escolha para a necrose aguda de retina. Entretanto, por ser uma doença rapidamente progressiva, a injeção intravítrea de aciclovir ao diagnóstico pode ser utilizada como terapia adjuvante, enquanto o aciclovir sistêmico ainda não alcançou níveis terapêuticos na retina. Os objetivos deste estudo experimental foram determinar a meia-vida do aciclovir no vítreo após injeção intravítrea e determinar os efeitos funcionais e morfológicos do aciclovir na retina de coelhos saudáveis após injeção intravítrea do medicamento em diferentes doses. MÉTODOS: Foram utilizados 32 coelhos albinos da raça New Zealand (estudo farmacológico) e 86 coelhos pigmentados da raça Dutch Belted (30 no estudo eletrofisiológico, 36 no estudo morfológico com microscopia de luz e 20 no estudo morfológico com imuno-histoquímica). Para a determinação da meia-vida do aciclovir no vítreo, os 32 coelhos albinos receberam injeção intravítrea de aciclovir 1 mg e foram sacrificados nos dias 2, 9, 14 e 28. Para a avaliação funcional e microscopia de luz, os 66 coelhos pigmentados receberam três doses intravítreas de aciclovir (0,1; 1 ou 10 mg) no olho direito e soro fisiológico no olho esquerdo. Destes, 30 animais foram submetidos ao eletrorretinograma (ERG) antes da injeção e nos dias 2, 7 e 15 após a injeção. Para a análise histológica (microscopia de luz), 36 animais foram sacrificados 2, 7 e 15 dias após a injeção. Para imuno-histoquímica (apoptose, GFAP, DAPI e vimentina), os 20 coelhos pigmentados receberam injeção intravítrea de 1 e 10 mg de aciclovir e foram sacrificados após cinco dias. RESULTADOS: No estudo da meia-vida do aciclovir no vítreo, as concentrações médias de aciclovir no vítreo foram 0,25, 0,09, 0,06 e 0,08 ?g/ml, respectivamente 2, 9, 14 e 28 dias depois da injeção. Nos estudos eletrofisiológico e de microscopia de luz, os olhos que receberam injeção intravítrea de 0,1 mg de aciclovir não apresentaram alterações funcionais ou histológicas. Os olhos injetados com 1 mg de aciclovir apresentaram redução significativa da amplitude das ondas a e b no ERG e desalinhamento dos fotorreceptores na microscopia de luz. Estes achados regrediram no 15º dia. Os olhos que receberam injeção intravítrea de 10 mg de aciclovir apresentaram as mesmas alterações funcionais, mas que não regrediram após o 15º dia. À microscopia de luz, esses olhos apresentaram destruição da camada de fotorreceptores e desorganização de toda a retina. Na camada de células ganglionares houve áreas com ausência de células da retina interna. A imuno-histoquímica mostrou lesão das células de Müller e apoptose de fotorreceptores apenas nos animais injetados com 10 mg. CONCLUSÕES: A meia-vida do aciclovir no vítreo após injeção intravítrea é muito curta para a sua detecção em dias. Os resultados funcionais e morfológicos sugerem que a injeção intravítrea de aciclovir em coelhos causa alterações tóxicas dose e tempo dependentes nos fotorreceptores e nos neurônios pós-receptorais da retina. A dose de 0,1 mg de aciclovir parece ser segura para injeção intravítrea em coelhos e pode ser utilizada em modelos experimentais de uveíte ou retinite viral / OBJECTIVE: The gold standard for the treatment of acute retinal necrosis is the use of systemic intravenous acyclovir. Nevertheless, as a rapidly progressive disease, use of intravitreal acyclovir injection at the time of diagnosis may be a second therapy until the systemic acyclovir reaches therapeutic levels in the retina. The aim of this experimental study was to determine pharmacological levels of the drug in the vitreous within days and to determine the functional and morphologic effects of acyclovir in the retina of healthy rabbits, after intravitreal injections in different dosages. METHODS: We have used 32 albino New Zealand rabbits for the pharmacologic experiments and 86 pigmented Dutch Belted animals for electrophysiology, immunochemistry and morphology. Thirty rabbits were used for the electrophysiological study, 36 were used for the light microscopy morphology and 20 animals were used for immunochemistry morphology. For the half-life study, the 32 albino rabbits received a 1mg acyclovir intravitreal injection and they were euthanized at 2, 9, 14 and 28 days. For functional and morphologic evaluations, the 66 pigmented animals received one of 3 intravitreal dosages of acyclovir (0,1; 1 or 10 mg) in the right eye and saline in the left eye. For the functional evaluation, 30 pigmented animals underwent electroretinography before the injection and on days 2, 7 and 15 after the procedure. For the histology with light microscopy, 36 animals were euthanized on days 2, 7 and 15 after the injection. Twenty rabbits that received 1 and 10mg of acyclovir were euthanized on day 5 were used for the immunohistochemistry to evaluate apoptosis, with GFAP, DAPI and vimentin. RESULTS: For the pharmacology study, the mean acyclovir concentrations when 1?g/ml was injected into the vitreous were respectively 0,25; 0,09; 0,06 e 0,08?g/ml on days 2, 9, 14 and 28 after injected. The eyes that received 0,1 mg acyclovir showed no functional or histological alterations. The eyes injected with 1 mg acyclovir had significant reduction on a and b waves amplitude and photoreceptor misalignment, which regressed on day 15. The 10mg injected eyes, showed the same electrophysiology changes. The retinas of those animals had photoreceptor layer destruction and total retina disorganization. In the ganglion cell layer, there were areas of absence of internal retinal cells. The immunohistochemistry showed Müller cells lesion and photoreceptor apoptosis in the 10mg animals. CONCLUSIONS: Acyclovir half-life is too short for its detection within days. The functional and morphological results suggest that the intravitreal acyclovir injection in rabbits cause toxic changes that are dose and time dependent on photoreceptors and post-receptor neurons in the retina. The 0,1 mg acyclovir dosage seems to be safe for intravitreal use in rabbits and may be studied in experimental models of viral uveitis or retinitis

Submitted by Marcos Anselmo (marcos.anselmo@unipampa.edu.br) on 2016-09-22T19:30:32Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) JESSICA BRANDAO REOLON.pdf: 405938 bytes, checksum: 02d1f792d3137ced3fc728e0e11dcb3e (MD5) / Approved for entry into archive by Marcos Anselmo (marcos.anselmo@unipampa.edu.br) on 2016-09-22T19:34:00Z (GMT) No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) JESSICA BRANDAO REOLON.pdf: 405938 bytes, checksum: 02d1f792d3137ced3fc728e0e11dcb3e (MD5) / Made available in DSpace on 2016-09-22T19:34:01Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) JESSICA BRANDAO REOLON.pdf: 405938 bytes, checksum: 02d1f792d3137ced3fc728e0e11dcb3e (MD5) Previous issue date: 2016 / O herpesvírus simples (HSV) é um importante problema de saúde pública em vários países provocando ulceração genital. Dentre o arsenal terapêutico para o tratamento da infecção por HSV destaca-se o aciclovir (ACV). No entanto, este apresenta limitações no seu uso como um tempo de meia-vida curto e uma baixa solubilidade aquosa. A curcumina (CUR) é um composto natural que vem demonstrando diversas atividades terapêuticas, dentre estas a atividade antiviral, porém o seu uso por via oral também é comprometido pela baixa solubilidade em água. A encapsulação em micropartículas poliméricas (MPs) é uma abordagem farmacotécnica que podem superar as dificuldades do uso terapêutico destes dois compostos. Em vista disto, o presente trabalho visou desenvolver e caracterizar MPs pelo método de aspersão compostas por HPMC e Eudragit® RS100 como materiais poliméricos, além de manitol como adjuvante de secagem. Os resultados demonstraram que o método de preparo por aspersão (spray drying) apresentou um rendimento em torno de 50% para todas as formulações desenvolvidas, mostrando um fluxo tecnológico mais vantajoso para as partículas sem manitol. O doseamento demonstrou teores de 82 a 99% e de 81 a 94%, para ACV e CUR, respectivamente. A análise granulométrica mostrou micropartículas de tamanho micrométrico entre 8,7 e 15,3 μm. A análise morfológica evidenciou o formato esférico e confirmou o resultado das análises de tamanho. A espectroscopia na região do infravermelho mostrou uma sobreposição dos espectros obtidos pelos componentes isolados indicando boa compatibilidade entre os materiais. O perfil de liberação in vitro permitiu observar que as MPs foram capazes de controlar a liberação e melhorar a solubilidade dos compostos, destacando-se, neste quesito, as MPs compostas por HPMC. A avaliação preliminar da atividade antiviral in vitro demonstrou que a associação de ACV e CUR possui um efeito sinérgico frente ao vírus BoVH-1, sendo que as MPs foram capazes de potencializar este efeito. Neste contexto, as MPs mostraram-se sistemas promissores para a veiculação de ACV e CUR por via oral, com elevado potencial para constituir um tratamento alternativo para o herpes viral. / The herpes simplex virus (HSV), also known as human herpes virus, infects humans causing mainly genital and labial ulcerations. Among the drugs available for the treatment of HSV infection the acyclovir (ACV) is an effective antiviral drug. However this drug presents limitations in its use due to the short half-life and low water solubility. Curcumin (CUR) has demonstrated several therapeutic activities, including antiviral activity, but the oral administration of this natural compound is also compromised by low solubility. The polymeric microparticles (MP) are a pharmacotechnical approach that modifies the pharmacokinetics of the compounds and offers a possibility to overcome the difficulties of the therapeutic use. In view of this, this study aimed to develop MPs by spray drying method composed of HPMC and Eudragit® RS100 as polymeric materials, and mannitol as drying material. The results showed a yield around 50% for all developed formulations and a better technological flow rate for the particles without mannitol. The assay showed levels 82-99 and 81% to 94%, to ACV and CUR, respectively. The particle size analysis showed microparticles micrometric size between 8.7 and 15.3 micrometers. Morphological analysis showed the spherical shape and confirmed the results of size analysis. Spectroscopy in the infrared showed an overlap of the spectra obtained by the individual components indicating good compatibility between the materials. The in vitro release profile observed that the PMs were able to control the release and improved the solubility of the compounds, especially when composed of HPMC. Besides, an in vitro preliminary assessment of antiviral activity demonstrated that the combination of ACV and CUR presented a synergistic effect against BoVH-1 virus, and the MPs were able to enhance this effect. The MPs showed to be promising systems for the oral administration of ACV and CUR and could be an improved alternative treatment for viral herpes.

INTRODUÇÃO: A administração de aciclovir por via sistêmica é o tratamento de escolha para a necrose aguda de retina. Entretanto, por ser uma doença rapidamente progressiva, a injeção intravítrea de aciclovir ao diagnóstico pode ser utilizada como terapia adjuvante, enquanto o aciclovir sistêmico ainda não alcançou níveis terapêuticos na retina. Os objetivos deste estudo experimental foram determinar a meia-vida do aciclovir no vítreo após injeção intravítrea e determinar os efeitos funcionais e morfológicos do aciclovir na retina de coelhos saudáveis após injeção intravítrea do medicamento em diferentes doses. MÉTODOS: Foram utilizados 32 coelhos albinos da raça New Zealand (estudo farmacológico) e 86 coelhos pigmentados da raça Dutch Belted (30 no estudo eletrofisiológico, 36 no estudo morfológico com microscopia de luz e 20 no estudo morfológico com imuno-histoquímica). Para a determinação da meia-vida do aciclovir no vítreo, os 32 coelhos albinos receberam injeção intravítrea de aciclovir 1 mg e foram sacrificados nos dias 2, 9, 14 e 28. Para a avaliação funcional e microscopia de luz, os 66 coelhos pigmentados receberam três doses intravítreas de aciclovir (0,1; 1 ou 10 mg) no olho direito e soro fisiológico no olho esquerdo. Destes, 30 animais foram submetidos ao eletrorretinograma (ERG) antes da injeção e nos dias 2, 7 e 15 após a injeção. Para a análise histológica (microscopia de luz), 36 animais foram sacrificados 2, 7 e 15 dias após a injeção. Para imuno-histoquímica (apoptose, GFAP, DAPI e vimentina), os 20 coelhos pigmentados receberam injeção intravítrea de 1 e 10 mg de aciclovir e foram sacrificados após cinco dias. RESULTADOS: No estudo da meia-vida do aciclovir no vítreo, as concentrações médias de aciclovir no vítreo foram 0,25, 0,09, 0,06 e 0,08 ?g/ml, respectivamente 2, 9, 14 e 28 dias depois da injeção. Nos estudos eletrofisiológico e de microscopia de luz, os olhos que receberam injeção intravítrea de 0,1 mg de aciclovir não apresentaram alterações funcionais ou histológicas. Os olhos injetados com 1 mg de aciclovir apresentaram redução significativa da amplitude das ondas a e b no ERG e desalinhamento dos fotorreceptores na microscopia de luz. Estes achados regrediram no 15º dia. Os olhos que receberam injeção intravítrea de 10 mg de aciclovir apresentaram as mesmas alterações funcionais, mas que não regrediram após o 15º dia. À microscopia de luz, esses olhos apresentaram destruição da camada de fotorreceptores e desorganização de toda a retina. Na camada de células ganglionares houve áreas com ausência de células da retina interna. A imuno-histoquímica mostrou lesão das células de Müller e apoptose de fotorreceptores apenas nos animais injetados com 10 mg. CONCLUSÕES: A meia-vida do aciclovir no vítreo após injeção intravítrea é muito curta para a sua detecção em dias. Os resultados funcionais e morfológicos sugerem que a injeção intravítrea de aciclovir em coelhos causa alterações tóxicas dose e tempo dependentes nos fotorreceptores e nos neurônios pós-receptorais da retina. A dose de 0,1 mg de aciclovir parece ser segura para injeção intravítrea em coelhos e pode ser utilizada em modelos experimentais de uveíte ou retinite viral / OBJECTIVE: The gold standard for the treatment of acute retinal necrosis is the use of systemic intravenous acyclovir. Nevertheless, as a rapidly progressive disease, use of intravitreal acyclovir injection at the time of diagnosis may be a second therapy until the systemic acyclovir reaches therapeutic levels in the retina. The aim of this experimental study was to determine pharmacological levels of the drug in the vitreous within days and to determine the functional and morphologic effects of acyclovir in the retina of healthy rabbits, after intravitreal injections in different dosages. METHODS: We have used 32 albino New Zealand rabbits for the pharmacologic experiments and 86 pigmented Dutch Belted animals for electrophysiology, immunochemistry and morphology. Thirty rabbits were used for the electrophysiological study, 36 were used for the light microscopy morphology and 20 animals were used for immunochemistry morphology. For the half-life study, the 32 albino rabbits received a 1mg acyclovir intravitreal injection and they were euthanized at 2, 9, 14 and 28 days. For functional and morphologic evaluations, the 66 pigmented animals received one of 3 intravitreal dosages of acyclovir (0,1; 1 or 10 mg) in the right eye and saline in the left eye. For the functional evaluation, 30 pigmented animals underwent electroretinography before the injection and on days 2, 7 and 15 after the procedure. For the histology with light microscopy, 36 animals were euthanized on days 2, 7 and 15 after the injection. Twenty rabbits that received 1 and 10mg of acyclovir were euthanized on day 5 were used for the immunohistochemistry to evaluate apoptosis, with GFAP, DAPI and vimentin. RESULTS: For the pharmacology study, the mean acyclovir concentrations when 1?g/ml was injected into the vitreous were respectively 0,25; 0,09; 0,06 e 0,08?g/ml on days 2, 9, 14 and 28 after injected. The eyes that received 0,1 mg acyclovir showed no functional or histological alterations. The eyes injected with 1 mg acyclovir had significant reduction on a and b waves amplitude and photoreceptor misalignment, which regressed on day 15. The 10mg injected eyes, showed the same electrophysiology changes. The retinas of those animals had photoreceptor layer destruction and total retina disorganization. In the ganglion cell layer, there were areas of absence of internal retinal cells. The immunohistochemistry showed Müller cells lesion and photoreceptor apoptosis in the 10mg animals. CONCLUSIONS: Acyclovir half-life is too short for its detection within days. The functional and morphological results suggest that the intravitreal acyclovir injection in rabbits cause toxic changes that are dose and time dependent on photoreceptors and post-receptor neurons in the retina. The 0,1 mg acyclovir dosage seems to be safe for intravitreal use in rabbits and may be studied in experimental models of viral uveitis or retinitis

Made available in DSpace on 2016-03-15T19:36:55Z (GMT). No. of bitstreams: 1 Kelly Cristini Bertachini.pdf: 2103840 bytes, checksum: 660079f6465adb541730be86f9ddd866 (MD5) Previous issue date: 2016-01-21 / Fundo Mackenzie de Pesquisa / The pseudoboehmite is a nanomaterial of fine ceramics type, used in pharmaceutical synthesis and nanosystems to release molecules. It is a material that was obtained by the Mackenzie University materials engineering group by different methods, precipitation and inorganic polymerization. This study investigated the controlled release acyclovir using pseudoboehmite, with emphasis on the determination of acyclovir content in tests carried out by liquid chromatography High Performance (HPLC). Assays were performed "in vivo," demonstrating the effect of addition of pseudoboehmite in controlled drug release. Its controlled release was assessed by the results of analysis of the drug concentration of acyclovir in plasma of "wistar rats", determined by HPLC according to the administration time of the drug in the tests "in vivo". It was concluded that the pseudoboehmite has a role in the controlled release over time, showing that it has higher efficiency compared with the drug administration "wistar rats" without pseudoboehmite. The results showed that the concentration of acyclovir is lower in rats that were gavage with pseudoboehmite. / A pseudoboemita é um nanomaterial do tipo cerâmica fina, usada em sínteses farmacêuticas e nanosistemas para liberação de moléculas. É um material que foi obtido pelo grupo de engenharia de materiais da Universidade Presbiteriana Mackenzie por diferentes métodos, precipitação e polimerização inorgânica. Este trabalho pesquisou a liberação controlada de aciclovir com o uso de pseudoboemita, dando ênfase na determinação do teor de aciclovir em ensaios realizados pela técnica de Cromatografia Líquida de Alta Eficiência (CLAE). Foram realizados ensaios in vivo , demonstrando o efeito da adição da pseudoboemita na liberação controlada do fármaco. Sua liberação controlada foi avaliada pelos resultados da análise de concentração do fármaco aciclovir no plasma sanguíneo de wistar rats , determinada por CLAE em função do tempo de administração do fármaco nos ensaios in vivo . Concluiu-se que a pseudoboemita teve um papel importante na liberação controlada em relação ao tempo, demonstrando que teve maior eficiência comparando-se com a administração do fármaco em wistar rats sem a pseudoboemita. Os resultados mostraram que a concentração de aciclovir é menor nos ratos em que a gavagem foi com pseudoboemita.

Métodos in vitro utilizando epitélio intestinal animal são importantes ferramentas para avaliar a permeabilidade de fármacos, propriedade que é um importante parâmetro de biodiosponibilidade. Considerando que o maior objetivo na indústria farmacêutica é desenvolver novos fármacos com boa biodisponibilidade oral, o projeto teve como objetivo padronizar o modelo de permeação com membrana de intestino de rã (Rana catesbeiana) em células de Franz, comparando seus resultados com ensaios de células Caco-2. Os fármacos modelo utilizados foram os antivirais zidovudina e aciclovir. A quantidade de fármaco permeado foi determinada por método de eletroforese capilar para o método com intestino de rã touro e por HPLC-UV para os ensaios com células Caco-2. O parâmetro de permeação foi o coeficiente de permeabilidade aparente (Papp) dos fármacos para ambos modelos experimentais. Para estabelecimento do protocolo experimental dos estudos de permeabilidade intestinal de rã, foi proposto um projeto fracionado 24-1 com 4 ensaios adicionais usando o software Minitab, e as variáveis foram: secção intestinal, pH da solução de Ringer e temperatura. A análise do planejamento experimental feita pela estimativa dos parâmetros da regressão obtidos através dos resultados do modelo fatorial possibilitou a determinação dos coeficientes da equação matemática que definiu a influência das variáveis sobre o coeficiente de permeabilidade aparente dos fármacos. Os efeitos das variáveis pH e temperatura interpretados conjuntamente apresentaram interferência leve, porém as variáveis fármaco e secção intestinal interpretados juntos tiveram interferência importante, mostrando maior permeação dos fármacos através da secção inicial do intestino da rã. Os resultados de Papp foram: para o metoprolol, pelo método das células Caco-2 foi de 28 x 10-6 cm/s, valor que está de acordo com demais dados de células Caco-2 na literatura e o valor obtido com células de Franz que mais se adequada a estes resultados e demais disponíveis provenientes de outras técnicas na literatura, foi de 28,1 x 10-6 cm/s, em uma das condições do planejamento estatístico utilizando segmento final da membrana epitelial da rã. No caso do aciclovir, o resultado de Papp de 0,48 x 10-6 cm/s também obtido em uma das condições envolvendo segmento intestinal final da rã foi exatamente igual a o valor 0,48 x 10 - 6 cm/s, encontrado com células Caco-2 no presente estudo e estão de acordo com outros valores disponíveis na literatura por Trapani e colaboradores, 2004 e também com células Caco-2. Para zidovudina o valor de Papp obtido em uma das condições utilizando segmento intestinal inicial da rã, de 13 x 10-6 cm/s, foi a que mais se assemelhou ao obtido pela técnica de células Caco-2, 13,6 x 10-6 cm/s, e também está de acordo com demais dados da literatura. / There are lots of different in vitro technics in the literature using animal intestinal epithelium to estimate permeability of drugs, property that is an important parameter of bioavailabity. Considering that the main objective of Pharmaceutical Companies is the development of new drugs with good oral bioavailabity, the aim of this work was to standardize the permeability of antivirals using in vitro/ex vivo method of intestinal epithelium of Rana catesbeiana in Franz cells and compare these results to those obtained from studies using Caco-2 cells. Zidovudine and Acyclovir were selected as model drugs. The amount of drug permeated will be determined by the method of capillary electrophoresis for assays using Rana Catesbeiana and HPLC-UV for studies with Caco-2 cells. The permeation parameter determined was the apparent permeability coefficient (Papp) of drugs for both experimental models. To establish the experimental protocol to studies of intestinal permeability of frog, it was proposed a fractional 24-1 design with 4 additional tests using Minitab software and the variables were: intestinal section, pH of Ringer solution and temperature. The analysis of the experimental design made by the estimate of the regression parameters obtained from the factorial model results allowed the determination of the coefficients of the mathematical equation that defines the influence of the variables on the apparent permeability coefficient of acyclovir and zidovudine. The effects of pH and temperature interpreted jointly presented a slight interference, but the variables drug and intes tinal section interpreted together had major interference, showing greater permeation of drugs through the initial section of the intestine of the frog . The results of Papp were: for metoprolol, with the method of Caco-2 cells was 28 x 10-6 cm/s, a value which is consistent with other data of Caco-2 cells provided in the literature and the condition obtained with Franz cells that are most suitable for these and other results obtained from other techniques available in the literature, was 28.1 x 10-6 cm/s, provided with the final intestinal segment using frog epithelial membrane. In the case of acyclovir, the result of Papp of 0.48 x 10-6 cm/s obtained in one condition with final frog intestinal segment was exactly equal to the value of 0.48 x 10-6 cm/s, found with Caco-2 cells in the present study and are in agreement with other values available in the literature for Trapani and colegues, 2004 and also with Caco-2 cells. The Papp value for zidovudine obtained with the initial gut segment of frog, 13 x 10-6 cm /s was which more resembled that obtained by the technique of Caco-2 cells, 13.6 x 10-6 cm/s and is also consistent with other literature data.